ARIAD Pharmaceuticals News

CAMBRIDGE, Mass. -- -- ARIAD Pharmaceuticals, Inc. today announced that Harvey J. Berger, M.D., chairman and chief executive officer, and Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer, will provide an overview of the Company's business at two upcoming investor conferences: The Goldman Sachs 33rd ... (more)

Biotech stocks pop and pull back on news of Phase II and III clinical trial data, but real money is made and lost once it comes down to the dance with the FDA and tangible revenues.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia Boston CEO Conference to Feature CEOs of Alkermes plc , Alnylam Pharmaceuticals , Ariad Pharmaceuticals, Inc.

Ariad Announces Updated Findings from Pivotal Pace Trial of Ponatinib to Be Presented at Annual Meeting of American Society of Clinical Oncology CAMBRIDGE, Mass.

Many leading funds, including SAC Capital, Fidelity Investments, and Wellington Management, filed forms 13-D and 13-G with the SEC last week , indicating that they had amended their ownership in U.S. traded public companies.

CAMBRIDGE, Mass. -- -- ARIAD Pharmaceuticals, Inc. today announced that it will webcast its presentation at the Bank of America Merrill Lynch 2012 Health Care Conference in Las Vegas.

CAMBRIDGE, Mass. -- -- ARIAD Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2012 and provided an update on corporate developments.

So far, 2012 has been the best year for the biotechnology and drugs industry. So many stocks surged in the last four months based on clinical trial results, FDA approval, FDA advisory committee recommendation, European commission approval, recommendation from independent committees, partnerships with big pharmaceuticals, acquisitions, and so on.